ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Clinical trial NCT02773849 · COMPLETED
Trial details
- NCT number
- NCT02773849
- Sponsor
- Ferring Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-19
- Primary completion
- 2019-05-24
- Enrollment
- 157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.